News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AstraZeneca
< Previous
1
2
3
4
5
6
Next >
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities
December 23, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma
December 17, 2021
From
AstraZeneca
Via
Business Wire
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study
December 16, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
CALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial
December 12, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Inaugural Asia Summit on Global Health successfully explores healthcare landscape
November 25, 2021
From
AstraZeneca
Via
ACN Newswire
Inaugural Asia Summit on Global Health opens today
November 24, 2021
From
AstraZeneca
Via
ACN Newswire
Inaugural Asia Summit on Global Health highlights Hong Kong's advantages
November 17, 2021
From
AstraZeneca
Via
ACN Newswire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer
December 09, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
December 08, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care
December 03, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
November 30, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
New Analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention
November 18, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
November 17, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021
November 05, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
SAPHNELO Consistently Reduces Systemic Lupus Erythematosus Disease Activity Regardless of Disease Duration and Prior Treatment
November 01, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health Disparities
November 01, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI Plus Chemotherapy Significantly Improved Overall Survival in 1st-Line Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial at Interim Analysis
October 25, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca and Bob Harper Unveil the Survivors Have Heart Second Chance Portraits to Change the Face of Heart Attack Survivorship
October 21, 2021
From
AstraZeneca
Via
Business Wire
AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards
October 20, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
October 15, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
October 08, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US
October 05, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens
October 04, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases
September 27, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
LYNPARZA® (olaparib) in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer
September 24, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
September 18, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
September 18, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
September 18, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
September 17, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer
September 17, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.